Abstracts tagged "pregnancy"

Abstract Number: 1009 • ACR Convergence 2025
Pregnancy Outcomes and Comorbidities Among Individuals with Systemic Lupus Erythematosus: A Nationwide Study Using Publicly Funded Health Insurance Claims Data
Amadeia Rector¹, Sadaf Sediqi², Alyssa Howren² and Julia F Simard³, ¹Stanford University, San Francisco, CA, ²Stanford University, Palo Alto, CA, ³Stanford Medicine, Stanford, CA
Background/Purpose: Individuals with SLE are at increased risk for pregnancy complications such as preeclampsia and preterm delivery. As SLE is commonly diagnosed and active during…
Abstract Number: 2395 • ACR Convergence 2025
Analysis of histopathological changes in the placenta of patients with systemic lupus erythematosus
Bartira Melo¹, Elizabeth Avvad², Marcela lacerda², Nilson jesus², Evandro Klumb² and Guilherme Ramires de Jesus³, ¹UERJ- Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²UERJ - Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ³Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Rio de Janeiro, Brazil
Background/Purpose: Systemic lupus erythematosus (SLE) is more frequent in women of reproductive age and pregnancy in these patients is considered as high risk. The inflammatory…
Abstract Number: 2208 • ACR Convergence 2025
Contraception and Pregnancy Experiences of Veterans from Minoritized Populations with Rheumatoid Arthritis
Catherine Sims¹, Yujung Choi², Abigail Shapiro³, Elizabeth Strawbridge², Jennifer Gierisch¹, Teresa Howard², Ankoor Shah¹ and Karen Goldstein¹, ¹VA Durham Healthcare System, Duke University, Durham, ²VA Durham Healthcare System, Durham, ³VA Durham Healthcare System, Cleveland
Background/Purpose: More than 8,500 women Veterans carry a diagnosis of rheumatoid arthritis (RA), however, there are limited data on the reproductive health and experiences of…
Abstract Number: 0933 • ACR Convergence 2025
Spatial Transcriptomics Reveal Altered Immune Dynamics Regulating Placental Development In a Humanized-TLR8 Mouse Model of Spontaneous Anti-Phospholipid Antibody Induced Pregnancy Loss
Yunwei Xia¹, Paul Hoover², Arnon Arazi³ and Anne Davidson¹, ¹Feinstein Institutes for Medical Research, Manhasset, NY, ²Brigham and Women's Hospital, Boston, MA, ³Feinstein Institutes for Medical Research, Acton, MA
Background/Purpose: TLR8 has been implicated in adverse outcomes of human pregnancy. We previously reported a mouse model of spontaneous aPL-induced pregnancy loss in Sle1 mice…
Abstract Number: 2225 • ACR Convergence 2025
The Impact of Pregnancy Planning on the Prevalence of Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: A Retrospective Study from Three Japanese Tertiary Referral Centers
Takehiro Nakai¹, Nanase Honda², YORIKAZU HASHIMOTO³, Eri Soga⁴, Sho Fukui⁵, Ayako Kitada⁶, Kensuke Nakanishi⁷, Naoto Yokogawa⁸ and Masato Okada⁹, ¹Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, ²Tokyo Metropolitan Matsuzawa hospital, Setagaya-ku, Tokyo, Japan, ³Nanbu Medical Center & Children's Medical Center, Naha, Japan, ⁴Tokyo Metropolitan Tama Medical Center, Tama, Tokyo, Japan, ⁵Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, ⁶St Luke's International hospital, nagareyama-shi, chiba- ken, Japan, ⁷Okinawa Prefectural Nanbu Medical Center & Children's Medical Center, Haebaru, Okinawa, Japan, ⁸Tokyo Metropolitan Tama Medical Center, Taito City, Tokyo, Tokyo, Japan, ⁹St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with a higher risk of adverse pregnancy outcomes (APOs) compared to the general population. Although several APO risk…
Abstract Number: 2206 • ACR Convergence 2025
Adolescents with Systemic Lupus Erythematosus at Highest Risk of Adverse Pregnancy Outcomes
Catherine Deffendall¹, Sarah Green², Ashley Suh², Bryan Han² and April Barnado², ¹Vanderbilt University, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Few studies exist that examine pregnancy outcomes in adolescents with SLE. To our knowledge, there have been no studies comparing SLE adolescent pregnancies to…
Abstract Number: 0626 • ACR Convergence 2025
Evaluation of Novel Anti-ATP1A1 Autoantibodies by ELISA to Predict Cardiac Neonatal Lupus (Cardiac-NL)
Nalani Sachan¹, Philip Carlucci², Mala Masson³, Nicola Fraser¹, Peter Izmirly⁴, Camila Hernández-Blanco⁵, Robert Clancy⁶, Bettina Cuneo⁷ and Jill Buyon¹, ¹NYU Grossman School of Medicine, New York, NY, ²New York University School of Medicine, New York, NY, ³NYU Langone Medical Center- Division of Rheumatology, New York, NY, ⁴New York University Grossman School of Medicine, New York, NY, ⁵NYU Langone Health, New York, NY, ⁶Columbia University, New York, NY, ⁷University of Arizona College of Medicine, Tucson, AZ
Background/Purpose: For childbearing women with SLE and other autoimmune diseases, the nearly invariant association of cardiac-NL with maternal SSA/Ro52/60kD autoantibodies supports the necessity of these…
Abstract Number: 2224 • ACR Convergence 2025
Failure of Steroid and Antimalarial Therapy to Normalize Placental Interferon and Angiogenic Gene Expression in SLE
Seemal Faisal¹, Alexandra Anderson², Luke Sharrock³, James Tran⁴ and Milena Vukelic⁵, ¹Louisiana State University Health Science Center New Orleans, New Orleans, ²Louisiana State University Health Science Center New Orleans, Phoenix, AZ, ³Louisiana State University Health Science Center, New Orleans, LA, ⁴Louisiana State University Health Science Center, New Orleans, ⁵Rheumatology Fellowship Program Director Louisiana State University, New Orleans, LA
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with an increased risk of placental insufficiency and adverse pregnancy outcomes, even when the disease is clinically quiescent.…
Abstract Number: 2205 • ACR Convergence 2025
Effectiveness of Reproductive Health Counseling for Rheumatology Patients
Caroline Maretz¹, Daniele Marcy², Kristin Sturm³, JoAnn Zell³ and Kristen Demoruelle⁴, ¹University of Colorado Anschutz Medical Campus, Denver, CO, ²University of Colorado, Northglenn, CO, ³University of Colorado Anschutz Medical Campus, Aurora, CO, ⁴University of Colorado Anschutz Medical Campus, Golden, CO
Background/Purpose: Systemic autoimmune diseases are often treated with medications that have known teratogenic effects or unknown safety profiles in pregnancy. As these diseases frequently affect…
Abstract Number: 0610 • ACR Convergence 2025
The Role of Active Nephritis, Compared to Active Non-Renal SLE, in Pregnancy Outcomes
Emma Trachman¹, Amanda Eudy² and Megan Clowse³, ¹Duke University, Durham, NC, ²Duke University, Raleigh, NC, ³Duke University, Chapel Hill, NC
Background/Purpose: The ACR recommends against pregnancy in patients with SLE with high disease activity. These recommendations do not distinguish between the various manifestations of active…
Abstract Number: 2223 • ACR Convergence 2025
Improving collaboration between rheumatology and OBGYN in the reproductive health care of patients with rheumatic disease
Sara Heard¹, Isha Vasudeva², Juvena Hitt² and Jeanne Gosselin³, ¹University of Vermont Medical Center, Burlington, VT, ²University of Vermont Medical Center, Burlington, ³University of Vermont Medical Center, Waterbury, VT
Background/Purpose: Contraception management, preconception planning, and prenatal, antenatal, and postnatal care vary significantly in clinical practice for patients with rheumatic disease. Rheumatologists recognize the need…
Abstract Number: 2203 • ACR Convergence 2025
Maternal and Fetal Outcomes Associated with IL-17 Inhibitor Exposure During Pregnancy in Patients with Seronegative Arthritis: A Case Series of Nine
Arshdeep Waring¹, Sofia Rieger-Torres², Jeremiah Tan³, Viktoria Pavlova⁴ and Neda Amiri⁵, ¹University of British Columbia, Abbotsford, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴McMaster University, Ancaster, ON, Canada, ⁵University of British Columbia, North Vancouver, BC, Canada
Background/Purpose: Interleukin-17 (IL-17) inhibitors, such as ixekizumab and secukinumab, are increasingly used in the treatment of seronegative inflammatory arthritis, including psoriatic arthritis and axial spondyloarthritis.…
Abstract Number: 0859 • ACR Convergence 2025
Trophoblast Dysfunction and Placental Alterations in a Mouse Model of Antiphospholipid Syndrome: The Potential Role of Neutrophil Extracellular Traps
Bruna Mazetto Fonseca¹, Srilakshmi Yalavarthi², Katarina Kmetova², NaveenKumar Somanathapura³, Cyrus Sarosh⁴, Kavya Sugur⁵, Wenying Liang⁶, Yu (Ray) Zuo³, Richard W. Lieberman⁶ and Jason S. Knight³, ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, ³University of Michigan, Ann arbor, MI, ⁴University of Michigan, Temperance, MI, ⁵Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Ann Arbor, MI, ⁶University of Michigan, Ann arbor
Background/Purpose: Neutrophil extracellular traps (NETs) are webs of chromatin and proteases (e.g., neutrophil elastase) that have been implicated in antiphospholipid syndrome (APS)-associated thrombosis; however, their…
Abstract Number: 2222 • ACR Convergence 2025
Neonatal Myocardial Strain in Offspring born to Mothers with Systemic Lupus Erythematosus: Pilot Data from the LEGACY Cohort
Reem Farhat¹, Lawrence Rudski², Natalie Dayan³, Catherine Henin⁴, Daniela Villegas Martinez⁴, Sariya Sahussarungsi¹, Pasinee Kanaprach¹, Sasha Bernatsky⁵, Gabriel Altit⁴ and Evelyne Vinet⁵, ¹McGill University, Faculty of Medicine and Health Sciences, Montreal, QC, Canada, ²Jewish General Hospital, Montreal, QC, Canada, ³McGill University Health Centre, Montreal, QC, Canada, ⁴Montreal Children's Hospital, Montreal, QC, Canada, ⁵Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) increases the risk of placenta-mediated adverse pregnancy outcomes (APO) and may impact offspring cardiovascular health. Transplacental maternal anti-Ro antibodies can…
Abstract Number: 2202 • ACR Convergence 2025
Epidemiologic Evaluation of Postpartum Mental Health for Women Living with Systemic Lupus Erythematosus: A Population-Based Cohort Study Among Medicaid Enrollees
Alyssa Howren¹, Amadeia Rector², Sadaf Sediqi³ and Julia F Simard⁴, ¹Stanford University, Menlo Park, CA, ²Stanford University, San Francisco, CA, ³Stanford University, Palo Alto, CA, ⁴Stanford Medicine, Stanford, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune rheumatic disease, predominately affecting women during their reproductive years. Despite widespread evidence that individuals with SLE…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].